Management of renal dysfunction in multiple myeloma

Current Treatment Options in Oncology

Volumn 4, Issue 3, 2003, Pages 239-246

  Pandit, Sandeep R ^a   Vesole, David H ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

Hematopoietic Stem Cell Transplantation; Hypercalcemia; Multiple Myeloma; Thalidomide; Zoledronic Acid

Indexed keywords

ANTINEOPLASTIC AGENT;

HUMAN; KIDNEY FAILURE; MULTIPLE MYELOMA; RENAL REPLACEMENT THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY FAILURE; MULTIPLE MYELOMA; RENAL DIALYSIS;

EID: 0141449245     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0025-8     Document Type: Article

References (37)

1. Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bence-Jones proteins. N Engl J Med 1991, 324:1845–1851. DOI: 10.1056/NEJM199106273242603
2. Khamlichi AA, Rocca A, Touchard G, et al.: Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 1995, 86:3655–3659.
3. Pozzi C, Fogazzi GB, Banfi G, et al.: Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995, 43:281–287.
4. Kyle RA: Monoclonal proteins and renal disease. Annu Rev Med 1994, 45:71–77. DOI: 10.1146/annurev.med.45.1.71
5. Clark AD, Shetty A, Soutar R: Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999, 13:79–90. DOI: 10.1016/S0268-960X(99)90014-0
6. Barlogie B, Alexanian R, Jagannath S: Plasma cell dyscrasias. JAMA 1992, 268:2946–2951. DOI: 10.1001/jama.268.20.2946
7. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000, 65:175–181. A study showing the prognostic importance of reversibility of renal failure, which improves long-term survival. DOI: 10.1034/j.1600-0609.2000.90221.x
8. Sakhuja V, Jha V, Varma S, et al.: Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000, 22:465–477. DOI: 10.1081/JDI-100100888
9. Solling K, Solling J: Clearance of Bence-Jones proteins during peritoneal dialysis or plasmapheresis in myelomatosis associated with renal failure. Contrib Nephrol 1988, 68:259–262.
10. Iggo N, Palmer AB, Severn A, et al.: Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989, 73:903–910.
11. Zucchelli P, Pasquali S, Cagnoli L, et al.: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988, 33:1175–1180. DOI: 10.1038/ki.1988.127
12. Moist L, Nesrallah G, Kortas C, et al.: Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol 1999, 19:45–50. DOI: 10.1159/000013424
13. Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J Clin Oncol 1998, 16:593–602.
14. Berenson JR, Hillner BE, Kyle R, et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20:3719–3736. The most recent American Society of Clinical Oncology guidelines for use of bisphosphonates in MM. DOI: 10.1200/JCO.2002.06.037
15. Misiani R, Tiraboschi G, Mingardi G, et al.: Management of myeloma kidney: an anti-light chain approach. Am J Kidney Dis 1987, 10:28–33.
16. Badros A, Barlogie B, Siegel E, et al.: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822–829. A larger trial reporting the feasibility and possible favorable outcomes of autotransplants in patients with MM with nonreversible renal insufficiency. DOI: 10.1046/j.1365-2141.2001.03033.x
17. Sheil AGR, Flavel S, Disney APS, et al.: Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc 1985, 17:1685–1688.
18. Osterborg A, Ehrsson H, Eksborg S, et al.: Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur J Clin Oncol 1989, 25:899–903. DOI: 10.1016/0277-5379(89)90138-7
19. Alexanian R, Dimopoulos MA: Management of multiple myeloma. Semin Hematol 1995, 32:20–30.
20. Alexanian R, Dimopoulos MA, Delasalle K, et al.: Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80:887–890.
21. Vacca A, Ribatti D, Roncali L, et al.: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87:503–508.
22. Singhal S, Mehta J, Barlogie B, et al.: Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1571. DOI: 10.1056/NEJM199911183412102
23. Rajkumar SV, Hayman S, Gertz MA, et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 20:4319–4323. A key study showing the efficacy and feasibility of thalidomide and dexamethasone in newly diagnosed MM and possible use as an alternative induction therapy regimen before transplant. DOI: 10.1200/JCO.2002.02.116
24. Attal M, Harousseau JL, Stoppa AM, et al.: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91–97. DOI: 10.1056/NEJM199607113350204
25. Attal M, Harousseau JL, Facon T, et al.: Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 94) [abstract]. Blood 2002, 100:7. A report of long-term follow-up (7 years) confirming improved OS in patients with MM who undergo double autologous transplantation in MM.
26. Tosi P, Zamagni E, Ronconi S, et al.: Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000, 14:1310–1313. DOI: 10.1038/sj.leu.2401819
27. Lee CK, Barlogie B, Zangari M, et al.: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant [abstract]. Blood 2002, 100:1670. A study showing the feasibility of high-dose melphalan therapy and autotransplantation in dialysis-dependent patients with MM. DOI: 10.1182/blood-2001-12-0263
28. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000, 1:28–36. A study reporting significance of presence of abnormal renal function at the time of transplant showed a higher incidence of TRM in this group of patients. DOI: 10.1038/sj.thj.6200003
29. Tricot G, Gazitt Y, Leemhuis T, et al.: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high-dose therapy in multiple myeloma. Blood 1998, 91:4489–4495.
30. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18:3031–3037.
31. Giralt S, Weber D, Aleman A, et al.: Non-myeloablative conditioning with fludarabine/melphalan (FM) for patients with multiple myeloma [abstract]. Blood 1999, 94:1549.
32. Lalancette M, Rezvani K, Szydlo R, et al.: Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk multiple myeloma: the EBMT experience [abstract]. Blood 2000, 96:872.
33. Joshua DE, Brown RD, Gibson J: Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994, 88:667–671.
34. Oivanen TM: Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group. Br J Haematol 1996, 92:834–839. DOI: 10.1046/j.1365-2141.1996.413952.x
35. Westin J, Rodjer S, Turesson I, et al.: IFN alpha-2b versus no maintenance treatment during the plateau phase on multiple myeloma: a randomized study. Br J Haematol 1995, 89:561–568.
36. Browman GP, Bergsagel D, Sicheri D, et al.: Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995, 13:2354–2360.
37. Brinker B, Waller E, Langston AA, et al.: Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma [abstract]. Blood 2002, 100:667.